Duvakitug - Teva Pharmaceuticals
Alternative Names: SAR-447189; TEV-48574; TEV’574Latest Information Update: 20 Dec 2024
Price :
$50 *
At a glance
- Originator Teva Pharmaceutical Industries
- Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor ligand superfamily member 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma; Crohn's disease; Ulcerative colitis
Most Recent Events
- 17 Dec 2024 Efficacy and adverse event data from the phase IIb RELIEVE UCCD LTE trial in Ulcerative colitis released by Teva Pharmaceuticals
- 17 Dec 2024 Teva Pharmaceuticals plans a phase III trial for Ulcerative colitis and Crohn's disease
- 26 Jul 2024 Teva Pharmaceuticals completes enrolment in its phase II RELIEVE UCCD trial for ulcerative colitis and Crohn's disease in US, Czech republic, Austria, Bulgaria, Germany, Hungary, Israel, Italy, Japan, Poland, Slovakia, Spain, Ukraine, United kingdom